Ipsen Consumer HealthCare is the historical activity of Ipsen: a long-standing expertise in gastrointestinal (GI) disorders developed over more than 45 years, and a global footprint in 80 countries.
Our brands related in 4 main therapeutic areas (GI, cognitive disorders, pain, cough and cold.) have strong medical and commercial value, allowing for sustainable and shared growth with our partners.
We believe every day matters
At Ipsen Consumer HealthCare, we are committed to taking care of patients and consumers around the world, by providing comfort and relief when they need it most. We work with our partners and healthcare professionals to deliver a broad range of healthcare solutions that help people get the most out of every day.
We pursue a three-fold ambition: establishing a growing, autonomous and sustainable consumer healthcare business.
Over the years, we have developed a portfolio of well-known brands that we continue to consolidate. These strong foundations have led us to strengthen our position in key European markets (France, Italy), and capture market growth in emerging markets such as Russia, China and Algeria.
In addition to leveraging our key brands (Smecta®, Forlax® & Tanakan®), we are extending our capabilities to include new solutions like medical devices and food supplements.
Our diversity of expertise allows us to go further and adapt faster in order to deliver superior value to patients and shareholders
20 key brands
4 disease areas
276.8 M€ sales
Ipsen’s history shows how entrepreneurship, ambition and tenacity have transformed the small-town French pharmacy created in 1929, into a global leader in specialty care. With this same mindset, we are transforming our heritage in primary care into a successful Consumer HealthCare business with a global outlook.
Ipsen’s long-standing expertise in consumer HealthCare spans the value chain, from active ingredient, to finished product, to the patient, with special expertise, in gastrointestinal (GI) disorders.
Over the decades, we have developed an expertise in clay-based products as well as Gingko Biloba natural extracts. This expertise has led to the launch of brands such as Smecta® for diarrhea, Forlax® for constipation, Fortrans® and Eziclen®/Izinova® colon-cleansing solutions, Tanakan® for cognitive disorders.
The 5 most recent illustrations of our transformation
We have revitalized this activity by enriching our capabilities, reinforcing our portfolio and expanding our geographical footprint.
New formulations and new partnerships have been developed to better serve the needs of patients around the world.
We signed an agreement with the Swedish firm Probi for the commercialization of the probiotic strain Lactobacillus plantarum 299v (LP299V®).
We acquired (from Sanofi and Boehringer ingelheim) five consumer healthcare products in some European territories. This transaction further accelerated the development of our Consumer HealthCare business and our conversion into an OTx (combined prescription and over-the-counter) business model.
We acquired 100% of the Italian company Akkadeas Pharma, whose diversified portfolio includes probiotics, medical devices and food supplements. In addition to providing a springboard for Ipsen’s future development in Italy, Akkadeas has become our Italian distributor for Smecta® (distributed under the brand name Diosmectal® in Italy).
We acquired (from Novascon) Floractin®, a range of probiotics in Poland.
Floractin® brand was launched in 2013 and includes Food supplements (FS) and Food specialties for medical purposes (FSMP) under different galenic: drops, powder and capsules produced and commercialized in Poland. Building on well-known strains such as Rhamnosus GG and Boulardii and recommended by the Polish Pediatrician association. Floractin® range targets babies, children and adults offering probiotic and rehydration solutions recommended by scientific societies (WGO, ESPGHAN, FISPGHAN) in acute gastroenteritis in addition to ORS treatment.
Because every day matters to each of us, Ipsen Consumer Healthcare constantly innovates for the benefit of both patients and consumers, offering a large portfolio of drugs, medical devices and food supplements solutions that are scientifically proven and recognized by healthcare professionals.
Today, almost 75% of Ipsen Consumer HealthCare revenues are realized in gastroenterology.
We develop and deliver healthcare solutions that will be needed today and tomorrow across the world. Ipsen’s international footprint, the strong medical and commercial value of our healthcare solutions, and a proven manufacturing excellence are the basis of our successful commercial and scientific partnerships.
The quality and efficacy of our leading brands is trusted in 80 countries across the world.
Ipsen Consumer HealthCare Division today offers a global presence, balanced between Europe and key emerging markets such as China, Russia and Algeria.
Ipsen CHC has a direct presence in 13 countries across the world.
Commercial and scientific partnerships
Ipsen has a proven track-record on entering into successful long-term agreements including acquisitions, in-licensing, out-licensing and other co-marketing and co-promotion projects across the world.
Expertise and competencies
Our internal industrial affairs team embed state-of-the-art facilities and high quality standards with outstanding competencies in clays, macrogol, sachets and liquid sticks as well as product development skills to fulfill a robust and successful innovation pipeline.
Our industrial team has also developed an expertise in managing successful technical transfers, collaborating with external manufacturers and contract manufacturing for external customers (CMO).
Ipsen CHC regularly invests in its industrial sites to keep them at the forefront of technology and efficiency, meeting strict quality and safety criteria.
70% of our world production comes from France, with 2 manufacturing sites:
- Dreux (Eure-et-Loire): development and production
All manufacture, packaging and storage of Ipsen Consumer HealtCare’s oral medicines (sachets, tablets, capsules, liquid forms, sticks) is carried out at the Dreux site.
- L’Isle-sur-la-Sorgue (Vaucluse): The Global Production and Advanced Research Centre for Natural Therapeutic Clay. 2/3rd of production is dedicated to European and Chinese markets.
Our industrial site in China (Tianjin) is dedicated to the Chinese market.
Those 3 sites continuously work to improve their social and environmental impacts across the value chain: they are certified ISO 14001 (environment) and OHSAS 18001 (safety and health) and target the Certification 50001 (energy savings) for 2021.
They are also Good Manufacturing Practioners (GMPs).
Ipsen also owns, together with Schwabe, one joint-venture in Cork (Irland) and one in Riazzino (Switzerland) dedicated to the production of natural plantation extracts (Ginkgo Biloba).
Our 1500 colleagues worldwide are united by their confidence in our business, and their desire to improve people’s quality of life every day.
By joining Ipsen Consumer HealthCare you will:
- Work for a global company with a strong reputation and a start-up mindset. Agility, entrepreneurship and trust are central to our way of doing business.
- Contribute to bringing care and comfort into the daily life of thousands of patients and families across the world, while keeping innovation and quality at the heart of everything you do.
- Benefit from a collaborative and open-minded culture, which offers a wealth of opportunities to talented and ambitious people.
Ipsen offers exciting opportunities that will challenge your abilities, expand your skills and reward your contribution in a positive atmosphere of personal and professional development.